Tamoxifen as initial endocrine therapy for metastatic breast cancer: Long term follow-up of two Piedmont Oncology Association (POA) trials

Breast Cancer Research and Treatment

Volumn 42, Issue 3, 1997, Pages 265-274

  Kuss, Jana T ^a   Muss, Hyman B ^a,b   Hoen, Helena ^a   Case, L Douglas ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Breast cancer; Endocrine therapy; Follow up; Metastatic; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LONG TERM CARE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOFT TISSUE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0031054478     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005758127114     Document Type: Article

References (18)

1. Petru E, Schmahl D: On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klinische Wochenschrift 65: 959-966, 1987
2. Henderson IC: Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW, (eds) Breast Diseases. 2nd ed. Lippincott, New York, 1991, pp. 559-603
3. Ingle JN: Principles of therapy in advanced breast cancer. Hematol Oncol Clin North Am 3: 743-763, 1989
4. Pritchard KI, Sutherland DJA: Diagnosis and therapy of breast cancer. The use of endocrine therapy. Hematol Oncol Clin North Am 3: 765-805, 1989
5. Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L: Overview of hormonal therapy in advanced breast cancer. Semin Oncol 17: 38-46, 1990
6. Muss HB: Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21: 15-26, 1992
7. Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL et al.: Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - A phase III trial of the Piedmont Oncology Association (POA). J Clin Oncol 6: 1098-1106, 1988
8. Muss HB, Case LD, Atkins JN, Bearden JD, Cooper MR, Cruz JM et al.: Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer. A Piedmont Oncology Association study. J Clin Oncol 12: 1630-1638, 1994
9. Muss HB, Case LD, Fussell R, Atkins J, Bearden J, Capizzi R et al.: Tamoxifen versus high-dose oral medroxyprogesterone acetate as first line endocrine therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 10: 41, 1991
10. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1293, 1977
11. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5: 255-260, 1986
12. Mattsson W: A phase III trial of treatment with tamoxifen versus treatment with high dose medroxyprogesterone-acetate in advanced postmenopausal breast cancer. In: Iacobelli S, Di Marco A (eds) Role of Medroxyprogesterone in Endocrine-Related Tumors. Raven Press. New York 1980, pp. 65-71
13. Pannuti F, Martoni A, Fruet F, Burroni P, Canova N, Hall S: Oral high dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer. In: Iacobelli S (ed) The role of tamoxifen in breast cancer. Raven Press, New York, 1982, pp. 85-92
14. van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DF: Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenoausal patients with advanced breast cancer. Cancer 58:7-13, 1986
15. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP et al.: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284-1291, 1992
16. Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS: Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: An analysis of patients entered on four prospective clinical trials. Cancer 77: 683-690, 1996
17. Anonymous. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 4: 186-193, 1986
18. Taylor SG, Gelman RS, Falkson G, Cummings FJ: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 10: 455-461, 1986